<DOC>
	<DOCNO>NCT02998697</DOCNO>
	<brief_summary>The purpose study determine efficacy Ferrous Sulphate ( FS ) tablets improve iron store functional capacity HF patient Iron Deficiency Anemia ( IDA ) .</brief_summary>
	<brief_title>Short Term Oral Iron Supplementation Systolic Heart Failure Patients Suffering From Iron Deficiency Anemia</brief_title>
	<detailed_description>The investigator conduct double blind randomize control trial ( RCT ) enrol 54 Heart Failure ( HF ) patient ( LVEF &lt; 50 % ) IDA ( Ferritin &lt; 100 ng/mL 100-300 ng/mL Tsat &lt; 20 % ) outpatient clinic National Cardiovascular Center Harapan Kita January July 2016 . Patients randomize 1:1 receive FS placebo 90 day , investigator evaluate change 6-Minute Walking Test ( 6MWT ) distance primary end-point change N-Terminal-pro Brain Natriuretic Peptide ( NT-proBNP ) post 6MWT serum lactate level secondary end-points .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Heart Failure , Systolic</mesh_term>
	<criteria>Age ≥ 18 year old Systolic heart failure patient without clinical sign decompensation outpatient clinic New York Heart Association ( NYHA ) functional class IIIII able perform 6MWT LVEF &lt; 50 % On heart failure therapy Haemoglobin ( Hb ) &lt; 13 gr/dL ( male ) ; Hb &lt; 12 gr/dL ( female ) &gt; 8 gr/dL Ferritin &lt; 100 µg/L Ferritin 100300 µg/L dengan Transferrin saturation ( Tsat ) &lt; 20 % Agree participate History : active bleeding , infection , malignancy , haematological abnormality , peptic ulcer History myocardial revascularization ( CABG/PCI ) within 3 month Acute Coronary Syndrome ( ACS ) , stroke , Transient Ischemic Attack ( TIA ) within 3 month Know allergic reaction Ferrous sulfate History intravenous iron administration within 1 month Permanent Pace Maker ( PPM ) /Implantable Cardiac Defibrillator ( ICD ) /Cardiac Resynchronization Therapy ( CRT ) estimate Glomerular Filtration Rate ( eGFR ) &lt; 30 ml/min/1.73m2 NTproBNP &gt; 4000 pg/ml ( patient without baseline data ) decrease level NTproBNP &lt; 30 % baseline Increase level serum alanine aminotransferase ( ALT ) / serum aspartate aminotransferase ( AST ) &gt; 3x normal value Moderate severe primary valvular heart disease Congenital heart disease Right heart failure due primary pulmonary hypertension , cor pulmonale , Chronic ThromboEmbolic Pulmonary Hypertension ( CTEPH )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Systolic Heart Failure</keyword>
	<keyword>Anemia</keyword>
	<keyword>Iron Deficiency</keyword>
</DOC>